LXRX

Lexicon Pharmaceuticals (LXRX)

About Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Details

Daily high

$2.15

Daily low

$1.98

Price at open

52 Week High

$2.53

52 Week Low

$0.71

Market cap

892.8M

Dividend yield

0.00%

Volume

157

Avg. volume

2.1M

P/E ratio

-28.11

Lexicon Pharmaceuticals News